Impaired lymphatic function accelerates cancer growth

Oncotarget

Volumn 7, Issue 29, 2016, Pages 45789-45802

  Steinskog, Eli Sihn Samdal ^a   Sagstad, Solfrid Johanne ^a   Wagner, Marek ^a   Karlsen, Tine Veronica ^a   Yang, Ning ^a   Markhus, Carl Erik ^a   Yndestad, Synnøve ^a,b   Wiig, Helge ^a   Eikesdal, Hans Petter ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Chy mice; IL 6; Lymphangiogenesis; Tumor associated macrophages

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; GROWTH ACCELERATION; HETEROZYGOSITY; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTERSTITIAL FLUID; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; SARCOMA CELL LINE; TISSUE PRESSURE; TUMOR GROWTH; ANIMAL; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; INTERLEUKIN-6; LYMPHANGIOGENESIS; MICE; MICE, MUTANT STRAINS; MUTATION; NEOPLASMS, EXPERIMENTAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84979910696     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9953     Document Type: Article

References (53)

1. Tacconi C, Correale C, Gandelli A, Spinelli A, Dejana E, D'Alessio S and Danese S. Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion. Gastroenterology. 2015; 148:1438-51.e8. doi: 10.1053/j.gastro.2015.03.005.
2. Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY and Van Laere S. Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis. The British journal of dermatology. 2014; 170:66-77.
3. Sundov Z, Tomic S, Alfirevic S, Sundov A, Capkun V, Nincevic Z, Nincevic J, Kunac N, Kontic M, Poljak N and Druzijanic N. Prognostic value of MVD, LVD and vascular invasion in lymph node-negative colon cancer. Hepatogastroenterology. 2013; 60:432-438.
4. Gao P, Zhou GY, Yin G, Liu Y, Liu ZY, Zhang J and Hao CY. Lymphatic vessel density as a prognostic indicator for patients with stage I cervical carcinoma. Hum Pathol. 2006; 37:719-725.
5. Li J, Yi H, Liu Z, Zhang H, Zhang D, Yue W, Jia H, Xu S and Li B. Association between VEGFR-3 expression and lymph node metastasis in non-small-cell lung cancer. Experimental and therapeutic medicine. 2015; 9:389-394.
6. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB and Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature reviews Cancer. 2014; 14:159-172.
7. Duong T, Koopman P and Francois M. Tumor lymphangiogenesis as a potential therapeutic target. J Oncol. 2012; 2012:204946.
8. Zheng W, Aspelund A and Alitalo K. Lymphangiogenic factors, mechanisms, and applications. The Journal of clinical investigation. 2014; 124:878-887.
9. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K and Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. American journal of human genetics. 2000; 67:295-301.
10. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE and Alitalo K. A model for gene therapy of human hereditary lymphedema. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:12677-12682.
11. Gordon K, Spiden SL, Connell FC, Brice G, Cottrell S, Short J, Taylor R, Jeffery S, Mortimer PS, Mansour S and Ostergaard P. FLT4/VEGFR3 and Milroy disease: novel mutations, a review of published variants and database update. Hum Mutat. 2013; 34:23-31.
12. Karlsen TV, Karkkainen MJ, Alitalo K and Wiig H. Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. J Physiol. 2006; 574:583-596.
13. Karlsen TV, McCormack E, Mujic M, Tenstad O and Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. American journal of physiology Heart and circulatory physiology. 2012; 302:H391-401.
14. Polacheck WJ, Charest JL and Kamm RD. Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:11115-11120.
15. Kimura T, Sugaya M, Oka T, Blauvelt A, Okochi H and Sato S. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. Oncotarget. 2015; 6:18081-18093. doi: 10.18632/oncotarget.4018.
16. Wiig H, Reed RK and Aukland K. Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to wick-in-needle technique. Microvascular research. 1981; 21:308-319.
17. Wiig H, Tveit E, Hultborn R, Reed RK and Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scandinavian journal of clinical and laboratory investigation. 1982; 42:159-164.
18. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, et al. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 2011; 13:1202-1213.
19. Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L and Dana R. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. The American journal of pathology. 2009; 175:1984-1992.
20. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory A, Falkowska-Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B and Goerdt S. Lymphatic endotheliumspecific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. The Journal of pathology. 2006; 209:67-77.
21. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA and Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012; 7:e47045.
22. Weisser SB, van Rooijen N and Sly LM. Depletion and reconstitution of macrophages in mice. Journal of visualized experiments. 2012;:4105.
23. Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G and Sood AK. Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer biology & therapy. 2014; 15:1061-1067.
24. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group. 2014 Annals of oncology. 2015; 26:259-271.
25. Esko JD and Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002; 71:435-471.
26. Hynes RO. The extracellular matrix: not just pretty fibrils. Science (New York, NY). 2009; 326:1216-1219.
27. Zhang Y, Cheng S, Zhang M, Zhen L, Pang D, Zhang Q and Li Z. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013; 8:e76147.
28. Platt AM, Rutkowski JM, Martel C, Kuan EL, Ivanov S, Swartz MA and Randolph GJ. Normal dendritic cell mobilization to lymph nodes under conditions of severe lymphatic hypoplasia. J Immunol. 2013; 190:4608-4620.
29. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007; 449:819-826.
30. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014; 41:14-20.
31. Sica A, Erreni M, Allavena P and Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015.
32. Mantovani A and Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015; 212:435-445.
33. Chanmee T, Ontong P, Konno K and Itano N. Tumorassociated macrophages as major players in the tumor microenvironment. Cancers. 2014; 6:1670-1690.
34. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N and Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. The journal of histochemistry and cytochemistry. 2006; 54:763-771.
35. Rossi JF, Lu ZY, Jourdan M and Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res. 2015; 21:1248-1257.
36. Howe LR, Subbaramaiah K, Hudis CA and Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clinical cancer research. 2013; 19:6074-6083.
37. Wagner M, Bjerkvig R, Wiig H, Melero-Martin JM, Lin RZ, Klagsbrun M and Dudley AC. Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis. Angiogenesis. 2012; 15:481-495.
38. Ghosh S and Ashcraft K. An IL-6 link between obesity and cancer. Frontiers in bioscience (Elite edition). 2013; 5:461-478.
39. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
40. Grivennikov SI, Greten FR and Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
41. Chang Q, Daly L and Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Seminars in immunology. 2014; 26:48-53.
42. Chen MF, Kuan FC, Yen TC, Lu MS, Lin PY, Chung YH, Chen WC and Lee KD. IL-6-stimulated CD11b+ CD14+ HLA-DR-myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 2014; 5:8716-8728 doi: 10.18632/oncotarget.2368.
43. Sumida K, Wakita D, Narita Y, Masuko K, Terada S, Watanabe K, Satoh T, Kitamura H and Nishimura T. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. European journal of immunology. 2012; 42:2060-2072.
44. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M and Jeannin P. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007; 110:4319-4330.
45. Chomarat P, Banchereau J, Davoust J and Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature immunology. 2000; 1:510-514.
46. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirstrom K, Gallagher WM, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical cancer research. 2011; 17:6083-6096.
47. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C and Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. The Journal of biological chemistry. 2009; 284:34342-34354.
48. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T and van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011; 187:1157-1165.
49. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Bronneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nature immunology. 2014; 15:423-430.
50. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS and Weichselbaum RR. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer research. 2010; 70:1534-1543.
51. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Akerud P, De Mol M, Salomaki H, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer cell. 2011; 19:31-44.
52. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL and Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002; 38:1564-1579.
53. Wiig H, Aukland K and Tenstad O. Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Heart Circ Physiol. 2003; 284:H416-424.